Is the CRISPR Treat Worth Two Licenses?

les Nouvelles - Journal of the Licensing Executives Society, Volume LIII No. 1, March 2018

3 Pages Posted: 7 Mar 2018 Last revised: 2 May 2018

See all articles by Adelaide Leitzel

Adelaide Leitzel

Taft Stettinius & Hollister, LLP

Neal Roach

Taft Stettinius & Hollister, LLP

Date Written: January 16, 2018

Abstract

Rivalries between universities extend beyond athletic fields.  UC-Berkeley scientists are in a full-fledged legal brawl with Harvard and MIT researchers over CRISPR technology. CRISPR technology allows very specific gene targeting and editing; it is even being used to image live cells.  The commercial potential associated with the CRISPR technology fuels the dispute over who invented the CRISPR technology and which group developed the CRISPR techniques and tools that work in eukaryotic cells, cells that perhaps have the most financial significance.  The international legal drama is see-sawing back and forth between UC-Berkeley and the Broad Institute which controls Harvard and MIT’s CRISPR technologies. Meanwhile life sciences companies seek an economical path to using CRISPR techniques.

Keywords: UC-Berkely, CRISPR, Harvard, MIT, technology, techniques, rivalries, treat worth

Suggested Citation

Leitzel, Adelaide and Roach, Neal, Is the CRISPR Treat Worth Two Licenses? (January 16, 2018). les Nouvelles - Journal of the Licensing Executives Society, Volume LIII No. 1, March 2018. Available at SSRN: https://ssrn.com/abstract=3103166

Adelaide Leitzel (Contact Author)

Taft Stettinius & Hollister, LLP ( email )

Cincinnati, OH
United States

Neal Roach

Taft Stettinius & Hollister, LLP ( email )

Cincinnati, OH
United States

Register to save articles to
your library

Register

Paper statistics

Downloads
8
Abstract Views
49
PlumX Metrics